Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-28T14:23:29.947Z Has data issue: false hasContentIssue false
  • English
  • Français

Vaccine prophylaxis of abattoir-associated Q fever: eight years' experience in Australian abattoirs

Published online by Cambridge University Press:  15 May 2009

B. P. Marmion ,
R. A. Ormsbee ,
M. Kyrkou ,
J. Wright ,
D. A. Worswick ,
A. A. Izzo ,
A. Esterman ,
B. Feery  and
R. A. Shapiro
B. P. Marmion*
Affiliation:
Division of Medical Virology, Institute of Medical and Veterinary Science; Department of Pathology, University of Adelaide; South Australia Health Commission, Adelaide; Commonwealth Serum Laboratories, Melbourne; Department of Social and Preventive Medicine, University of Queensland, Australia
R. A. Ormsbee
Affiliation:
Division of Medical Virology, Institute of Medical and Veterinary Science; Department of Pathology, University of Adelaide; South Australia Health Commission, Adelaide; Commonwealth Serum Laboratories, Melbourne; Department of Social and Preventive Medicine, University of Queensland, Australia
M. Kyrkou
Affiliation:
Division of Medical Virology, Institute of Medical and Veterinary Science; Department of Pathology, University of Adelaide; South Australia Health Commission, Adelaide; Commonwealth Serum Laboratories, Melbourne; Department of Social and Preventive Medicine, University of Queensland, Australia
J. Wright
Affiliation:
Division of Medical Virology, Institute of Medical and Veterinary Science; Department of Pathology, University of Adelaide; South Australia Health Commission, Adelaide; Commonwealth Serum Laboratories, Melbourne; Department of Social and Preventive Medicine, University of Queensland, Australia
D. A. Worswick
Affiliation:
Division of Medical Virology, Institute of Medical and Veterinary Science; Department of Pathology, University of Adelaide; South Australia Health Commission, Adelaide; Commonwealth Serum Laboratories, Melbourne; Department of Social and Preventive Medicine, University of Queensland, Australia
A. A. Izzo
Affiliation:
Division of Medical Virology, Institute of Medical and Veterinary Science; Department of Pathology, University of Adelaide; South Australia Health Commission, Adelaide; Commonwealth Serum Laboratories, Melbourne; Department of Social and Preventive Medicine, University of Queensland, Australia
A. Esterman
Affiliation:
Division of Medical Virology, Institute of Medical and Veterinary Science; Department of Pathology, University of Adelaide; South Australia Health Commission, Adelaide; Commonwealth Serum Laboratories, Melbourne; Department of Social and Preventive Medicine, University of Queensland, Australia
B. Feery
Affiliation:
Division of Medical Virology, Institute of Medical and Veterinary Science; Department of Pathology, University of Adelaide; South Australia Health Commission, Adelaide; Commonwealth Serum Laboratories, Melbourne; Department of Social and Preventive Medicine, University of Queensland, Australia
R. A. Shapiro
Affiliation:
Division of Medical Virology, Institute of Medical and Veterinary Science; Department of Pathology, University of Adelaide; South Australia Health Commission, Adelaide; Commonwealth Serum Laboratories, Melbourne; Department of Social and Preventive Medicine, University of Queensland, Australia
*
Professor B. P. Marmion, Department of Pathology, University of Adelaide, GPO Box 498, Adelaide, South Australia, 5000.
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

During the period 1981–8 a clinical trial of a Q fever vaccine (Q-vax; Commonwealth Serum Laboratories, Melbourne) has been conducted in abattoir workers and other at-risk groups in South Australia. Volunteers in four abattoirs and visitors to the abattoirs were given one subcutaneous dose of 30 μg of a formalin-inactivated, highly-purified Coxiella burnetii cells, Henzerling strain, Phase 1 antigenic state, in a volume of 0·5 ml.

During the period, over 4000 subjects have been vaccinated and the programme continues in the abattoirs and related groups. ‘Common’ reactions to the vaccine comprised tenderness and erythema, rarely oedema at the inoculation site and sometimes transient headache. Two more serious ‘uncommon’ reactions, immune abscess at the inoculation site, were observed in two subjects, and two others developed small subcutaneous lumps which gradually dispersed without intervention.

Protective efficacy of the vaccine appeared to be absolute and to last for 5 years at least. Eight Q fever cases were observed in vaccinees, but all were in persons vaccinated during the incubation period of a natural attack of Q fever before vaccine-induced immunity had had time (≥ 13 days after vaccination) to develop. On the other hand, 97 Q fever cases were detected in persons working in, or visiting the same abattoir environments.

Assays for antibody and cellular immunity showed an 80–82% seroconversion after vaccination, mostly IgM antibody to Phase 2 antigen, in the 3 months after vaccination. This fell to about 60%, mostly IgG antibody to Phase 1 antigen, after 20 months. On the other hand, 85–95% of vaccinees developed markers of cell mediated immunity as judged by lymphoproliferative responses with C. burnetii antigens; these rates remained elevated for at least 5 years.

The Q fever vaccine, unlike other killed rickettsial vaccines, has the property of stimulating long-lasting T lymphocyte memory and this may account for its unusual protective efficacy as a killed vaccine.

Type
Research Article
Information
Epidemiology & Infection , Volume 104 , Issue 2 , April 1990 , pp. 275 - 287
Copyright
Copyright © Cambridge University Press 1990

References

REFERENCES

Marmion, BP, Ormsbee, RA, Kyrkou, M, et al. Vaccine prophylaxis of abattoir-associated Q fever. Lancet 1984; ii: 1411–4.CrossRefGoogle Scholar
Marmion, BP. Development of Q fever vaccines, 1937–1967. Med J Aust 1967; ii: 1074–8.Google Scholar
Bell, FJ, Lackman, DB, Meis, A, Hadlow, WJ. Recurrent reaction at site of Q fever vaccination in a sensitized person. Military Medicine 1964: 129: 591–5.CrossRefGoogle Scholar
Meiklejohn, G, Lennette, EH.Q feverin California. 1. Observations on vaccination of human beings. Amer J Hyg 1950; 52: 54–64.Google Scholar
Stoker, MGP. Q fever down the drain. Brit Med J 1957; 1: 425–7.CrossRefGoogle ScholarPubMed
Benenson, AS. Q fever vaccine: efficacy and present status. In: Smadel JE, ed. Symposium on Q fever. Walter Reed Army Institute of Medical Science Publication No. 6, U.S. Government Printing Office, Washington D.C., 1959: 47–60.Google Scholar
Lackman, DB, Bell, EJ, Bell, JF, Picken, EG. Intradermal sensitivity testing in man with a purified vaccine for Q fever. Amer J Pub Hlth 1962: 52: 87–91.CrossRefGoogle ScholarPubMed
Kleinbaum, DG, Kupper, LL, Morgenstern, H. Epidemiologic research, principles and quantitative methods. Wadsworth, California: 1982.Google Scholar
Fiset, P. Review of status of Q fever vaccine and vaccine studies. Commission on Rickettsial Diseases, Armed Forces Epidemiology Board, 1970. Ormsbee RA, personal communication.Google Scholar
Fiset, P. Vaccination against Q fever. In: Proceedings of First International Congress on vaccines against viral and rickettsial diseases of man, PAHO Science Publication 1967; 147: 528.Google Scholar
Armitage, P, Berry, G.Statistical methods in medical research. Oxford: Blackwell Scientific Publications, 1987.Google Scholar
Worswick, D, Marmion, BP. Antibody responses in acute and chronic Q fever and in subjects vaccinated against Q fever. J Med Microbiol 1985; 19: 281–96.CrossRefGoogle ScholarPubMed
Ormsbee, RA. A method of purifying Coxiella burnetii and other pathogenic rickettsiae. J Immunol 1961; 88: 100–8.CrossRefGoogle Scholar
Ormsbee, R, Peacock, M, Philip, R, et al. Serological diagnosis of epidemic typhus fever. Amer J Epidemiol 1977; 105: 261–71.CrossRefGoogle ScholarPubMed
Izzo, A, Marmion, BP, Worswick, DA. Markers of cell-mediated immunity after vaccination with an inactivated whole cell Q fever vaccine. J Inf Dis 1988; 157: 781–9.CrossRefGoogle ScholarPubMed
Hackstadt, T, Peacock, MG, Hitchcock, PJ, Cole, RL. Lipopolysaccharide variation in Coxiella burnetii: intrastrain heterogenicity in structure and antigenicity. Infect Immun 1985; 48: 359–65.CrossRefGoogle ScholarPubMed
Hackstadt, T. Antigenic variation in the Phase I lipopolysaccharide of Coxiella burnetii isolates. Infect Immun 1986; 52: 337–40.CrossRefGoogle ScholarPubMed
Moos, A, Hackstadt, T. Comparative virulence of intra- and interstain lipopolysaccharide variants of Coxiella burnetii in the guinea pig model. Infect Immun 1987; 55: 1144–50.CrossRefGoogle Scholar
Ormsbee, RA, Marmion, BP. Prevention of Coxiella burnetii infection-vaccines and guidelines for those at risk. In: Marrie, T, ed. Q Fever, vol. I, The disease. Boca Raton, Florida: CRC Press. In press.Google Scholar